Controversial Reversal? Let's Talk DOACs
Anticoagulation is a pillar of treatment for thrombosis and various disorders resulting in thromboembolic complications, such as atrial fibrillation. However, direct oral anticoagulants (DOACS) contribute to subsequent increased morbidity and mortality from bleeds. This CE will educate pharmacists on the reversal agents for DOACs, which aid in the management of major bleeds complicated by DOAC use. Pharmacists will be introduced to appropriate anticoagulant reversal strategies based on the available expert consensus reports and published primary literature.
Learning Objectives
Upon completion of this activity, the participant will be able to:
- Explain the mechanism of action of DOAC reversal agents.
- Identify contraindications for therapy with reversal agents.
- Describe key points published within current literature to support recommendations for reversal agents.
- Construct a treatment plan for DOAC reversal patients in patients presenting with a major bleed.
Presenter
Jennifer Hammond, PharmD, is a PGY1 pharmacy resident at Baystate Medical Center in Springfield, Massachusetts. She obtained her Doctor of Pharmacy degree in May 2021 from the University of New England School of Pharmacy in Portland, Maine. Jennifer’s practice interests include critical care and emergency medicine.
Registration Fee: This module is provided free of charge to all.
Release Date: June 9, 2022
Expiration Date: June 9, 2023
Contact Hours: 1.0 (0.1 CEU)
ACPE UAN: 0026-0000-22-130-H01-P | Knowledge
ACPE Topic Designator: Disease State Management/Drug Therapy
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1.0 contact hour (0.1 CEU).
The policy of Massachusetts College of Pharmacy and Health Sciences is ensuring balance, independence, objectivity, and scientific rigor in all of its educational activities. Any individuals involved in planning or content creation for a continuing education activity are required to disclose financial relationships with ineligible companies that have occurred within the last 24 months. The intent of the policy is to identify and mitigate potential conflicts of interest that may affect the activity. All clinical medicine recommendations must be based on evidence accepted within the medical profession.
Jennifer Hammond has no relevant financial relationships with ineligible companies to disclose.
Residency Director Frank Szczerba has no relevant financial relationships with ineligible companies to disclose.
Off-label/investigational uses of Prothrombin Complex Concentrate (human) will be discussed.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies related to the content of this presentation.
Massachusetts College of Pharmacy and Health Sciences will identify, review, and mitigate all conflicts of interest disclosed prior to delivery of an educational activity to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but provides participants with information that may be of potential importance when they are evaluating content.